Daniil Berezhnoy

Dr. Daniil Berezhnoy

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2018 in Amino Acids
Verified
Journal Article
Closed access
PDF file
DBDaniil Berezhnoy
Daniil Berezhnoy
SSS. L. Stvolinsky
S. L. Stvolinsky
ALA. V. Lopachev
A. V. Lopachev
ADA. A. Devyatov
A. A. Devyatov
OLO. M. Lopacheva
O. M. Lopacheva
TFT. N. Fedorova
T. N. Fedorova

1 June 2018 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
OKOlga Kulikova
Olga Kulikova
DBDaniil Berezhnoy
Daniil Berezhnoy
SSSergey L. Stvolinsky
Sergey L. Stvolinsky
ALAlexander V Lopachev
Alexander V Lopachev
VOValentina S. Orlova
Valentina S. Orlova
TFTatiana Fedorova
Tatiana Fedorova

16 February 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
DTDmitry Troshev
Dmitry Troshev
DVDmitry N Voronkov
Dmitry N Voronkov
APAnastasia Pavlova
Anastasia Pavlova
DADenis Abaimov
Denis Abaimov
ALAlexander Latanov
Alexander Latanov
DBDaniil Berezhnoy
Daniil Berezhnoy
Parkinson’s disease (PD) is characterized by slow progression with a long prodromal stage and the gradual evolution of both neuropsychological symptoms and subtle motor changes, preceding motor dysfunction. Thus, in order for animal models of PD to be valid, they should reproduce these characteristics of the disease. One of such models, in which neuropathology is induced by chronic injections of low doses of mitochondrial toxin rotenone, is well established in rats. However, data on this model adapted to mice remain controversial. We have designed the study to describe the timecourse of motor and non-motor symptoms during chronic subcutaneous administration of rotenone (4 mg/kg daily for 35 days) in C57BL/6 mice. We characterize the underlying neuropathological processes (dopaminergic neuron degeneration, regional brain metabolism, monoamine neurotransmitter and lipid peroxidation changes) at different timepoints: 1 day, 2 weeks and 5 weeks of daily rotenone exposure. Based on the behavioral data, we can describe three stages of pathology: cognitive changes from week 2 of rotenone exposure, subtle motor changes in week 3–4 and motor dysfunction starting roughly from week 4. Neuropathological changes in this model include a general decrease in COX activity in different areas of the brain (acute effect of rotenone) and a more specific decrease in midbrain (chronic effect), followed by significant neurodegeneration in SNpc but not VTA by the 5th week of rotenone exposure. However, we were unable to find changes in the level of monoamine neurotransmitters neither in the striatum nor in the cortex, nor in the level of lipid peroxidation in the brainstem. Thus, the gradual progression of pathology in this model is linked with metabolic changes, rather than with oxidative stress or tonic neurotransmitter release levels. Overall, this study supports the idea that a low-dose rotenone mouse model can also reproduce different stages of PD as well as rats.

4 June 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
OKOlga Kulikova
Olga Kulikova
DTDmitry Troshev
Dmitry Troshev
DBDaniil Berezhnoy
Daniil Berezhnoy
SSSergey Stvolinsky
Sergey Stvolinsky
YTYulia Timoshina
Yulia Timoshina
TFTatiana Fedorova
Tatiana Fedorova
Oxidative stress, accompanied by mitochondrial dysfunction, is a key mechanism involved in the pathogenesis of Parkinson’s disease (PD). Both carnosine and lipoic acid are potent antioxidants, the applicability of which in therapy is hindered by their limited bioavailability. This study aimed to evaluate the neuroprotective properties of a nanomicellar complex of carnosine and lipoic acid (CLA) in a rotenone-induced rat model of PD. Parkinsonism was induced via the administration of 2 mg/kg rotenone over the course of 18 days. Two doses of intraperitoneal CLA (25 mg/kg and 50 mg/kg) were administered alongside rotenone to assess its neuroprotective effect. At 25 mg/kg CLA decreased muscle rigidity and partially restored locomotor activity in animals that received rotenone. Furthermore, it caused an overall increase in brain tissue antioxidant activity, accompanied by a 19% increase in neuron density in the substantia nigra and increased dopamine levels in the striatum relative to animals that only received rotenone. Based on the acquired results, it may be concluded that CLA have neuroprotective properties and could potentially be beneficial in PD treatment when used in conjunction with the base therapy.

1 October 2016 in Neurochemical Journal
Verified
Journal Article
Closed access
PDF file
DBDaniil Berezhnoy
Daniil Berezhnoy
TFT. N. Fedorova
T. N. Fedorova
SSS. L. Stvolinskii
S. L. Stvolinskii
AIA. N. Inozemtsev
A. N. Inozemtsev

1 December 2020 in Journal of Chemical Neuroanatomy
Verified
Journal Article
Closed access
DBDaniil Berezhnoy
Daniil Berezhnoy
DTDmitry Troshev
Dmitry Troshev
DNDenis Nalobin
Denis Nalobin
TFTatiana N. Fedorova
Tatiana N. Fedorova